TTRX (Turn Therapeutics Inc. Common Stock) Stock Analysis - Politician Trades
Turn Therapeutics Inc. Common Stock (TTRX) is a publicly traded the market company. As of May 21, 2026, TTRX trades at $4.48 with a market cap of $145.96M and a P/E ratio of -40.28. TTRX moved +0.00% today. Year to date, TTRX is +0.63%; over the trailing twelve months it is flat. Its 52-week range spans $2.57 to $26.50. Rallies surfaces TTRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded TTRX stock?
Rallies tracks politician and congressional stock disclosures for TTRX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Chaudhary Zuraiz bought 2.50K (~$8.75K) on Dec 12, 2025.
GOLDEN ARTHUR F bought 9.87K (~$33.95K) on Nov 24, 2025.
GOLDEN ARTHUR F bought 20.53K (~$58.93K) on Nov 21, 2025.
TTRX Analyst Consensus
TTRX analyst coverage data. Average price target: $0.00.
Common questions about TTRX
Which politicians traded TTRX stock?
Rallies tracks politician and congressional stock disclosures for TTRX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in TTRX?
Yes. Rallies tracks politician and congressional stock disclosures for TTRX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is TTRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TTRX. It does not provide personalized investment advice.